Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $38,171.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CEO Cedric Francois sold 1,900 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $20.09, for a total value of $38,171.00. Following the sale, the chief executive officer directly owned 342,333 shares of the company's stock, valued at approximately $6,877,469.97. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Monday, July 14th, Cedric Francois sold 137,465 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $20.19, for a total value of $2,775,418.35.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS traded up $0.52 during midday trading on Thursday, reaching $20.27. 565,822 shares of the company were exchanged, compared to its average volume of 2,358,897. The company has a current ratio of 4.08, a quick ratio of 3.62 and a debt-to-equity ratio of 2.76. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $41.94. The stock has a fifty day simple moving average of $18.14 and a 200 day simple moving average of $22.81. The stock has a market cap of $2.55 billion, a P/E ratio of -11.33 and a beta of 0.67.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The company had revenue of $149.90 million for the quarter, compared to analysts' expectations of $197.61 million. During the same period in the prior year, the business earned ($0.54) EPS. The business's quarterly revenue was down 3.2% compared to the same quarter last year. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on APLS shares. Robert W. Baird reduced their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Citigroup dropped their price target on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 22nd. Scotiabank lowered their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a research report on Thursday, May 8th. Royal Bank Of Canada reduced their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. Finally, Morgan Stanley increased their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 2nd. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $39.84.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its stake in shares of Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock worth $390,011,000 after acquiring an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. raised its holdings in Apellis Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company's stock valued at $221,551,000 after acquiring an additional 84,331 shares during the last quarter. AQR Capital Management LLC raised its holdings in Apellis Pharmaceuticals by 119.6% in the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock valued at $89,173,000 after acquiring an additional 2,220,977 shares during the last quarter. Geode Capital Management LLC raised its holdings in Apellis Pharmaceuticals by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock valued at $58,699,000 after acquiring an additional 28,426 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in Apellis Pharmaceuticals by 1.8% in the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company's stock valued at $56,748,000 after acquiring an additional 30,867 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).